A Phase 1, Double-Blinded Study to Evaluate the Safety, Tolerability, and Immunogenicity of Pandemic Influenza Plasmid DNA Vaccines

Trial Profile

A Phase 1, Double-Blinded Study to Evaluate the Safety, Tolerability, and Immunogenicity of Pandemic Influenza Plasmid DNA Vaccines

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Mar 2010

At a glance

  • Drugs Influenza A virus DNA vaccine-H5N1 (Primary) ; Vaxfectin
  • Indications Influenza A virus H5N1 subtype
  • Focus Adverse reactions
  • Sponsors Vical
  • Most Recent Events

    • 28 Jan 2010 Results published in Vaccine.
    • 29 Apr 2009 Results presented at the 12th Annual Conference on Vaccine Research, according to a Vical media release.
    • 13 Feb 2009 Results presented at the 5th WHO Meeting on Evaluation of Pandemic Influenza Prototype Vaccines in Clinical Trials as reported by Vical.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top